Clostridium Difficile

D. Borden Lacy and colleagues used cryo-electron microscopy to define the structure of a C. diff toxin, providing a framework for the design of novel therapeutics. Read More

An inexpensive generic drug once used to prevent gastrointestinal ulcers in people taking daily NSAIDs protects against C. diff infection in mice. Read More

According to the Centers for Disease Control and Prevention, in 2011 in the United States there were almost half a million Clostridium difficile infections, and one in 11 patients 65 or older with a healthcare-associated C. diff infection died within 30 days of diagnosis. Read More

Children who experience recurrent C. diff infections may have fecal inflammatory markers that could predict risk and improve management of these infections. Read More

Fecal transplants are increasingly being used to treat certain human illnesses and more scientists have begun to research the transplants' effects in animals. Read More

Researchers at Vanderbilt University Medical Center have obtained the crystal structure of a toxin from the bacterium Clostridium difficile (“C. diff”) — the leading cause of hospital-acquired diarrhea in the United States. Read More

Eric Skaar, Ph.D., MPH, the Ernest W. Goodpasture Professor of Pathology, has received a Scholar Award from the American Asthma Foundation (AAF). Read More

Vanderbilt University investigators have identified a cellular receptor for a toxin from Clostridium difficile (“C. diff”) — the leading cause of hospital-acquired diarrhea in the United States. Read More

Clostridium difficile on the intestinal lining. (Wellcome Images) Clostridium difficile (“C. diff”) infection is a leading cause of hospital-associated diarrhea, and the frequency and severity of infections are on the rise. D. Borden Lacy, Ph.D., associate professor of Pathology, Microbiology and Immunology, and colleagues recently demonstrated that the C. Read More